SEC Tracker
Get the app

Prokidney PROK

Prokidney FY 2022: diluted EPS −$0.23

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Prokidney reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Diluted EPS−$0.23No year-earlier figure tagged10-K income statement, on EDGAR
  2. Cash and cash equivalents$490.3M+111197% from $440K in FY 202110-K balance sheet, on EDGAR
  3. Cash from operations−$77.1MAgainst −$50.3M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Prokidney files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Parabilis Medicines PBLS
  2. Sutro Biopharma STRO public float $60M, Jun 30, 2025
  3. PDS Biotechnology PDSB public float $60M, Jun 30, 2025
  4. iBio IBIO public float $58M, Dec 31, 2025
  5. Medicinova MNOV public float $62M, Jun 30, 2025